Understand the source comparison
Peptides for Wound Healing Research: Comparison
The table below compares the primary peptide classes used in wound healing research based on mechanism, target phase, administration route, and evidence level. BPC-157 VEGF receptor agonism, angiogenesis stimulation Proliferation, remodeling 200–500 µg/kg subc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares the primary peptide classes used in wound healing research based on mechanism, target phase, administration route, and evidence level.
- BPC-157
- VEGF receptor agonism, angiogenesis stimulation
- Proliferation, remodeling
- 200–500 µg/kg subcutaneous
- Animal models, limited human trials
- Strong angiogenic effect; reproducible in rodent and porcine models
- TB-500 (Thymosin Beta-4)
- Actin upregulation, cell migration
- Inflammation resolution, proliferation
- 5–10 mg/kg subcutaneous
- Preclinical animal studies
- Well-documented migration effect; human data emerging
- GHK-Cu (Copper Peptide)
- Collagen synthesis, TGF-beta activation
- 1–5 µM topical or 0.5–2 mg/kg injectable
- In vitro, ex vivo, Phase II trials
- Strongest collagen deposition data; FDA-cleared in some formulations
- LL-37
- Antimicrobial membrane disruption, immune recruitment
- Inflammation, infection control
- 10–50 µM topical
- In vitro, infected wound models
- Effective against MRSA and Pseudomonas; stability challenges
- Thymosin Alpha-1
- Macrophage M1→M2 polarization, inflammation resolution
- Inflammation resolution
- 1.6–3.2 mg subcutaneous biweekly
- Chronic wound models, clinical case series
- Critical for chronic wounds; underutilized in acute models
- KPV
- NF-kappa B inhibition, anti-inflammatory
- Inflammation modulation
- 1–10 µM topical or injectable
- In vitro, colitis models
- Potent anti-inflammatory; limited wound-specific trials